文献速递肝病

慢性乙型肝炎患者停用替诺福韦后HBsAg清除率高于恩替卡韦

Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
PubMed 文献 · Aliment Pharmacol Ther · 2023-06-02

这项回顾性研究比较了无肝硬化慢性乙型肝炎患者停用恩替卡韦(n=556)与替诺福韦二吡呋酯(TDF,n=335)后HBsAg清除率,并纳入持续治疗至少4年的患者(n=677)作为持续组。停用TDF者7年HBsAg累积清除率为35.4%,停用恩替卡韦者为22.6%,停用TDF者清除率显著更高(全体p=0.019,倾向评分匹配后p=0.015)。

要点

  • 停用TDF者7年HBsAg累积清除率35.4%,停用恩替卡韦者22.6%。
  • 停用TDF者HBsAg清除率在全体(p=0.019)和倾向评分匹配后(p=0.015)均显著高于停用恩替卡韦者。
  • 停用TDF者病毒学复发、临床复发和再治疗率均高于停用恩替卡韦者。

核心结论

  • 停用TDF的患者HBsAg清除率显著高于停用恩替卡韦的患者,尤其是在停药后无HBV复发的亚组中。

研究设计与样本

  • 回顾性评估891例接受恩替卡韦(n=556)或TDF(n=335)且停药后随访至少12个月的无肝硬化慢性乙型肝炎患者。
  • 另纳入677例持续接受恩替卡韦或TDF治疗至少4年的患者作为持续组。

主要发现

  • 在HBeAg阳性和HBeAg阴性亚组中,停用TDF者的病毒学复发、临床复发和再治疗率均高于停用恩替卡韦者。
  • 整个停药队列中,恩替卡韦组和TDF组7年HBsAg累积清除率分别为22.6%和35.4%。
  • 停用TDF者HBsAg清除率在全体患者(p=0.019)和倾向评分匹配患者(p=0.015)中均显著高于停用恩替卡韦者,在达到持续应答的亚组中尤为明显(p<0.001)。
  • Cox回归分析显示,TDF、较长治疗时间和治疗结束时较低HBsAg水平与整个停药组的HBsAg清除独立相关。
  • 倾向评分匹配后,停药组HBsAg清除发生率显著高于持续组(p<0.001),包括HBeAg阳性和HBeAg阴性患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To compare the rates of hepatitis B surface antigen (HBsAg) loss after discontinuation of entecavir versus tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) without cirrhosis. METHODS: A total of 891 patients who received entecavir (n = 556) or TDF (n = 335) followed up post-treatment for at least 12 months were retrospectively assessed. A total of 677 patients who had continued entecavir or TDF therapy for at least 4 years were enrolled as the continued group. RESULTS: Patients who discontinued TDF had higher rates of virological and clinical relapse and retreatment than patients who discontinued entecavir in both the HBeAg-positive and HBeAg-negative subgroups. In the entire discontinued cohort, the cumulative rates of HBsAg loss at 7 years were 22.6% and 35.4% in the entecavir and TDF groups respectively. Patients who discontinued TDF had significantly higher rates of HBsAg loss than patients who discontinued entecavir therapy in all (p = 0.019) and propensity score-matched (p = 0.015) patients, especially among the subgroups who achieved a sustained response (p < 0.001). Cox regression analysis revealed that TDF, longer treatment duration and lower HBsAg levels at end of treatment were independently associated with HBsAg loss in the entire discontinued group. The incidence of HBsAg loss was significantly higher in the discontinued group than in the continued group after propensity score matching (p < 0.001), including HBeAg-positive and HBeAg-negative patients. CONCLUSIONS: Patients who discontinued TDF had significantly higher rates of HBsAg loss than patients who discontinued entecavir, especially among the subgroups without HBV relapse after cessation of therapy.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chen CH, Peng CY, Hu TH, et al. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2023. PMID: 37265196. doi:10.1111/apt.17602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。